This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
Provision of voluntary written informed consent by subject
CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
None
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit
Cohort
Prospective
Disease assessments
Diagnostic testCT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
Tumor Biopsy
Procedure/SurgeryTumor Biopsy per protocol
Blood test
Diagnostic testBlood Test per protocol
Overall Survival
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive
Overall Survival
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive
Overall Survival
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive
Overall Survival
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive
Click on the lead sponsor to view all of their trials.
Marcela V. Maus, M.D.,Ph.D.
Lead sponsor
Massachusetts General Hospital
Sponsor institution
